



## Entasis Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Conference in London

April 2, 2019

WALTHAM, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer, will present at the H.C. Wainwright & Co. Global Life Sciences Conference being held April 7-9, 2019 in London, UK.

Details of the presentation are below:

Event: H.C. Wainwright & Co. Global Life Sciences Conference

Date: Tuesday, April 9, 2019

Time: 11:10 AM GMT / 7:10 AM EDT

In addition to his presentation, Dr. Perros will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Entasis management should contact their H.C. Wainwright representatives.

### About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting *A. baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae*), and ETX0282CPDP (targeting *Enterobacteriaceae* infections). Entasis is also using its platform to develop a novel class of antibiotics, non- $\beta$ -lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit [www.entasistx.com](http://www.entasistx.com).

### Entasis Company Contact

Kyle Dow

Entasis Therapeutics

(781) 810-0114

[kyle.dow@entasistx.com](mailto:kyle.dow@entasistx.com)

### Investor Relations Contact

Lee Roth

The Ruth Group

(646) 536-7012

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

### Media Contact

Kirsten Thomas

The Ruth Group

(508) 280-6592

[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

Source: Entasis Therapeutics Holdings Inc.